GSK - GlaxoSmithKline plc

NYSE - Nasdaq Real Time Price. Currency in USD
39.580
+0.700 (+1.80%)
As of 12:52PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close38.880
Open39.540
Bid39.600 x 1800
Ask39.610 x 3100
Day's Range39.420 - 39.760
52 Week Range34.520 - 42.360
Volume1,772,130
Avg. Volume2,458,250
Market Cap95.435B
Beta (3Y Monthly)0.56
PE Ratio (TTM)44.77
EPS (TTM)0.884
Earnings DateFeb 1, 2017 - Feb 6, 2017
Forward Dividend & Yield1.98 (5.18%)
Ex-Dividend Date2018-08-09
1y Target Est44.30
Trade prices are not sourced from all markets
  • Trump administration: Drug makers should disclose prices in TV ads
    Yahoo Finance19 hours ago

    Trump administration: Drug makers should disclose prices in TV ads

    just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.

  • A Financial Overview of Bausch Health in October
    Market Realist4 days ago

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in the first half of 2017 to $4.1 billion in the first half of this year, reflecting an ~5.0% YoY (year-over-year) decline. In the second quarter, Bausch Health generated net revenues of $2.1 billion compared to $2.2 billion in the second quarter of 2017.

  • How Analysts View Bausch Health in October
    Market Realist4 days ago

    How Analysts View Bausch Health in October

    In the second quarter, Bausch Health (BHC) reported net income and diluted EPS of -$873.0 million and -$2.49, respectively, compared to -$38.0 million and -$0.11 in the second quarter of 2017. In the first half, Bausch Health generated net income and diluted EPS of -$3.45 million and -$9.84, respectively, compared to $590.0 million and $1.68 in the first half of 2017.

  • Analysts’ Estimates and Ratings for Novartis in October
    Market Realist5 days ago

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

  • A Closer Look at Novartis’s Innovative Medicines Segment
    Market Realist6 days ago

    A Closer Look at Novartis’s Innovative Medicines Segment

    Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

  • How Novartis’s Businesses Have Been Performing
    Market Realist6 days ago

    How Novartis’s Businesses Have Been Performing

    Novartis’s (NVS) business is separated into three segments: Innovative Medicines, the prescription medicines business Sandoz, the generics business Alcon, the eye care business

  • A Look at Novartis’s Valuation on October 9
    Market Realist7 days ago

    A Look at Novartis’s Valuation on October 9

    Novartis AG (NVS) reported EPS of $1.29 on revenue of $13.2 billion in the second quarter, reporting a 7% YoY (year-over-year) rise in revenue compared to $12.2 billion in the second quarter of 2017.

  • Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area
    American City Business Journals8 days ago

    Meet the $172.5 million biotech IPO from the U.K. with big plans to grow in the Bay Area

    Orchard Rx Ltd., a London-based gene therapy company targeting "bubble boy" disease and other rare genetic conditions, wants to raise $172.5 million through an initial public offering that in part will bankroll a key Bay Area expansion. Orchard, whose shareholders include drug giant GlaxoSmithKline plc (NYSE: GSK), is the latest biotech company to take advantage of Wall Street's open cash window. It filed its IPO plans Thursday, less than two months after raising $148 million in an oversubscribed Series C round.

  • Merck Reports Positive Efficacy Data from Phase III HIV Study
    Zacks11 days ago

    Merck Reports Positive Efficacy Data from Phase III HIV Study

    Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.

  • Gilead Announces Positive Data From Ongoing Biktarvy Study
    Zacks11 days ago

    Gilead Announces Positive Data From Ongoing Biktarvy Study

    Gilead (GILD) reports positive data from an ongoing late stage study on HIV regimen, Biktarvy at 96 weeks.

  • Analyzing Seattle Genetics’ Key Collaborations
    Market Realist11 days ago

    Analyzing Seattle Genetics’ Key Collaborations

    Seattle Genetics (SGEN) is focused on maximizing Adcetris’ market reach. Currently, the product is sold in 71 countries. Adcetris was approved in Japan for treating frontline Hodgkin lymphoma. Seattle Genetics has a global collaboration with Takeda Pharmaceutical (TKPYY) to develop and commercialize Adcetris. While Seattle Genetics retains rights for the drug in the United States and Canada, Takeda has the rights for the drug in the rest of the world. Takeda pays Seattle Genetics a royalty.

  • J&J's Phase III Data Shows Switch to its HIV Drug Beneficial
    Zacks12 days ago

    J&J's Phase III Data Shows Switch to its HIV Drug Beneficial

    Data from the 96-week long phase III EMERALD study shows that switching to J&J's (JNJ) Symtuza maintains high virologic suppression.

  • GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018
    Market Realist12 days ago

    GlaxoSmithKline ADR’s Performance and Revenues in Q3 2018

    GlaxoSmithKline (GSK) segregates its business portfolio into three business segments—Pharmaceuticals, Vaccines, and Consumer Healthcare. As a British multinational company, GlaxoSmithKline reports its revenues in pounds sterling. The chart below compares GlaxoSmithKline’s EPS and revenues since the first quarter of 2017, as well as its estimates for the third quarter.

  • The Wall Street Journal13 days ago

    [$$] Boston Pharma Adds to War Chest in Pacts With Novartis, GlaxoSmithKline

    Boston Pharmaceuticals Inc., a startup backed with a $600 million funding commitment from a single investor, is bulking up its portfolio of potential medications. PLC to add to its portfolio, securing three anti-infective programs from Novartis and five products from GSK, including drugs that could treat acne and irritable bowel syndrome.